-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] In recent years, China's pharmaceutical innovation market is in a period of rapid development, especially after the State Drug Administration has accelerated the process of drug R&D approval, the number of domestic companies deploying innovative drugs has been increasing
.
It is worth mentioning that with the continuous emergence of drug research and development results, the overseas transactions of Chinese pharmaceutical companies' innovative drugs have also begun to increase
.
A few days ago, Jinfang Pharmaceutical announced that it has reached a cooperation with SELLAS Life Sciences Group of the United States to license the global development and commercialization rights of the highly selective CDK9 inhibitor GFH009 outside the Greater China region (including mainland China, Hong Kong, Macau, and Taiwan) to SELLAS.
.
It is understood that CDK9 is one of the very potential targets of the CDK kinase family, and its activity is negatively correlated with the overall survival rate of patients with various types of cancer
.
According to the announcement, SELLAS will pay Jinfang a $10 million down payment and technology transfer fees, as well as a cumulative development and sales milestone payment of $140 million; it will also pay Jinfang Gradient royalties
.
At present, there is no highly selective CDK9 inhibitor approved for marketing globally
.
In China, GFH009 is the first highly selective CDK9 inhibitor to enter clinical trials.
It is also the first project independently developed by Jinfang and submitted to FDA for clinical approval.
Phase I clinical trial in patients with hematological malignancies
.
In addition to Jinfang Pharmaceuticals, Luye Pharma Group recently announced that its subsidiary Luye Pharma (Switzerland) has entered into an agreement with Exeltis Pharma Mexico, SA de CV and Exeltis Pharmaceuticals Holding, SL (Exeltis) to grant the latter a Mindor Day Transdermal Exclusive commercialization rights for the patch in Mexico and Poland
.
The data show that the Ristigmine Multi-Day Transdermal Patch is an innovative twice-weekly patch formulation of Ristigmine for the treatment of mild to moderate dementia associated with Alzheimer's disease
.
The product was developed by Luye Pharma's proprietary transdermal drug delivery technology platform and has obtained marketing approvals in several European countries
.
Also, before this, Tianyan Pharmaceutical (AGAD.
NS) also announced that it has reached a research cooperation and exclusive technology licensing agreement with the multinational pharmaceutical company Sanofi for an amount of up to 2.
5 billion US dollars
.
In this cooperation, Tianyan Pharmaceutical is responsible for early product development, using its safe antibody SAFEbody® technology to help Sanofi develop its new generation of monoclonal and bispecific antibodies with precise masked safety antibodies, while Sanofi will be responsible for The product will be further developed and commercialized in the future
.
The increasing amount and number of cooperation actually shows the increasing value of these pharmaceutical companies in the global market
.
The industry predicts that in the future, with the improvement of the strength of China's innovative drug companies, the layout of more companies will no longer be limited to the domestic market, and more innovative drugs will bravely go overseas
.
However, it should be noted that while the industry is generally optimistic about the prospect of domestic innovative drugs going overseas, it is also suggested that the export of innovative drugs to the sea is still hindered and long
.
From the perspective of industry insiders, Chinese pharmaceutical companies still need to further strengthen in terms of intellectual property layout, overseas clinical execution, overseas commercialization layout capabilities, and global business expansion
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
It is worth mentioning that with the continuous emergence of drug research and development results, the overseas transactions of Chinese pharmaceutical companies' innovative drugs have also begun to increase
.
A few days ago, Jinfang Pharmaceutical announced that it has reached a cooperation with SELLAS Life Sciences Group of the United States to license the global development and commercialization rights of the highly selective CDK9 inhibitor GFH009 outside the Greater China region (including mainland China, Hong Kong, Macau, and Taiwan) to SELLAS.
.
It is understood that CDK9 is one of the very potential targets of the CDK kinase family, and its activity is negatively correlated with the overall survival rate of patients with various types of cancer
.
According to the announcement, SELLAS will pay Jinfang a $10 million down payment and technology transfer fees, as well as a cumulative development and sales milestone payment of $140 million; it will also pay Jinfang Gradient royalties
.
At present, there is no highly selective CDK9 inhibitor approved for marketing globally
.
In China, GFH009 is the first highly selective CDK9 inhibitor to enter clinical trials.
It is also the first project independently developed by Jinfang and submitted to FDA for clinical approval.
Phase I clinical trial in patients with hematological malignancies
.
In addition to Jinfang Pharmaceuticals, Luye Pharma Group recently announced that its subsidiary Luye Pharma (Switzerland) has entered into an agreement with Exeltis Pharma Mexico, SA de CV and Exeltis Pharmaceuticals Holding, SL (Exeltis) to grant the latter a Mindor Day Transdermal Exclusive commercialization rights for the patch in Mexico and Poland
.
The data show that the Ristigmine Multi-Day Transdermal Patch is an innovative twice-weekly patch formulation of Ristigmine for the treatment of mild to moderate dementia associated with Alzheimer's disease
.
The product was developed by Luye Pharma's proprietary transdermal drug delivery technology platform and has obtained marketing approvals in several European countries
.
Also, before this, Tianyan Pharmaceutical (AGAD.
NS) also announced that it has reached a research cooperation and exclusive technology licensing agreement with the multinational pharmaceutical company Sanofi for an amount of up to 2.
5 billion US dollars
.
In this cooperation, Tianyan Pharmaceutical is responsible for early product development, using its safe antibody SAFEbody® technology to help Sanofi develop its new generation of monoclonal and bispecific antibodies with precise masked safety antibodies, while Sanofi will be responsible for The product will be further developed and commercialized in the future
.
The increasing amount and number of cooperation actually shows the increasing value of these pharmaceutical companies in the global market
.
The industry predicts that in the future, with the improvement of the strength of China's innovative drug companies, the layout of more companies will no longer be limited to the domestic market, and more innovative drugs will bravely go overseas
.
However, it should be noted that while the industry is generally optimistic about the prospect of domestic innovative drugs going overseas, it is also suggested that the export of innovative drugs to the sea is still hindered and long
.
From the perspective of industry insiders, Chinese pharmaceutical companies still need to further strengthen in terms of intellectual property layout, overseas clinical execution, overseas commercialization layout capabilities, and global business expansion
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
